Inozyme Pharma is led by an experienced management team with a proven track record in rare disease drug development, regulatory approvals, manufacturing and operations.

Leadership Team

Axel Bolte

Co-founder and Chief Executive Officer

Henric Bjarke

Senior Vice President and Chief Operating Officer

Steven Jungles

Senior Vice President and Chief Technical Operations Officer

Eric Yuen, M.D.

Senior Vice President and Chief Medical Officer

Ruhi Ahmed, Ph.D., RAC

Vice President of Regulatory and Government Affairs

Stephen Basso

Vice President of Finance

Lori Ann Correia, MS, CGC

Director, Clinical Operations and Patient Advocacy

Board of Directors

Joseph Schlessinger, Ph.D.

Chairman

Axel Bolte

Director

Reinaldo M. Diaz

Director

Ed Mathers

Director

Martin Edwards, Ph.D.

Director

Ruchita Sinha

Board Observer

Demetrios Braddock, M.D., Ph.D.

Board Observer

Scientific Advisory Board

Demetrios Braddock, M.D., Ph.D.

Scientific Founder and Chairperson


Joseph Schlessinger, Ph.D.


Enrique M. De La Cruz, Ph.D.


Jon S. Morrow, M.D., Ph.D.


Mark A. Lemmon, Ph.D.


Edward Y. Skolnik, M.D.


Robert Terkeltaub, M.D.


Clinical Advisory Board

Michael Levine, M.D.

Chairperson


Thomas O. Carpenter, M.D.


Frank Rutsch, M.D.


Axel Bolte

Co-founder and Chief Executive Officer

Axel Bolte co-founded Inozyme Pharma, together with Demetrios Braddock and Yossi Schlessinger. He serves as the President and Chief Executive Officer. Prior to joining Inozyme Pharma, Mr. Bolte had a successful 16-year career in healthcare venture capital and served as an investment advisor to HBM Partners AG, based in Zug, Switzerland, and previously New York City. During his time as a venture capitalist, Axel led multiple biopharma investments and has served on many boards of directors of private and public companies. He is currently a Director of Ophthotech (OPHT), Nabriva Therapeutics (NBRV) and Allena Pharmaceuticals (ALNA). He remains a Venture Partner at HBM Partners AG. Mr. Bolte completed studies in biochemistry and organic chemistry at the University of Cambridge and the Swiss Federal Institute of Technology in Zurich, Switzerland. He also earned an MBA from the University of St. Gallen, Switzerland.

Henric Bjarke

Senior Vice President and Chief Operating Officer

Henric Bjarke joined Inozyme Pharma in July 2017 and serves as Senior Vice President and Chief Operating Officer. Mr. Bjarke brings a wealth of experience in metabolic and rare diseases to Inozyme Pharma, having previously served as Vice President and Therapeutic Area Head for the Metabolic Business Unit at Alexion Pharmaceuticals. In this role, he was responsible for asfotase alfa for the treatment Hypophosphatasia and other development programs. Most resently, Mr. Bjarke was Chief Commercial Officer of Ophthotech, where he was responsible for building the U.S. commercial and operations infrastructure for Ophthotech’s product portfolio. Additionally, Mr. Bjarke has held multiple key supervisory roles with Pharmacia, Eyetech and Watson Pharmaceuticals, where he managed multiple U.S. and global brands and successfully oversaw several major launches. Mr. Bjarke earned a B.A.Sc. in business administration and economics from Uppsala University, Sweden.

Steven Jungles

Senior Vice President and Chief Technical Operations Officer

Steven Jungles joined Inozyme Pharma in May 2017 and currently serves as Senior Vice President and Chief Technical Operations Officer. In this role, Mr. Jungles is responsible for leading the process development, manufacturing, quality control and supply chain functions for Inozyme Pharma. Most recently, Mr. Jungles served as the Senior Vice President of Technical Operations at Ultragenyx Pharmaceutical, where he led the manufacturing organization and supply chain activities for the company. Prior to Ultragenyx, Mr. Jungles served as the Vice President of Contract Manufacturing and Supply Chain at BioMarin Pharmaceutical. During his twelve-year tenure at BioMarin, he served in a number of key positions primarily in the functional area of manufacturing. Previously, Mr. Jungles worked at Harvard Gene Therapy Initiative. Mr. Jungles earned his B.S. in biology from the University of Iowa.

Eric Yuen, M.D.

Senior Vice President and Chief Medical Officer

Eric Yuen joined Inozyme Pharma in June 2017 and serves as the Chief Medical Officer. He has developed biologics and small molecules for a variety of diseases, including a number of rare genetic diseases. Eric has led departments responsible for Phase I-IV development and submissions of numerous INDs, CTAs, NDAs and MAAs. Dr. Yuen’s industry experience began at Merck (2000-2004) as Director of Clinical Research, working on CNS and pain indications, followed by Johnson & Johnson (2004-2013) as Vice President of Clinical Development. At Johnson & Johnson, he served as the Therapeutic Area Head for CNS for 4 years, followed by the Head of Clinical Development for 4 years at a joint venture between Johnson & Johnson and Elan for their portfolio of monoclonal antibodies and vaccines targeting Alzheimer’s disease. More recently, Eric has worked with a number of biotechnology and pharmaceutical companies, helping to develop compounds targeting a variety of rare genetic diseases. Prior to industry, Dr. Yuen was an assistant professor of neurology at the University of Washington (1996-2000), where he conducted clinical research in rare disorders such as ALS and muscular dystrophies. Eric completed his undergraduate education at Stanford University, M.D. from the University of Chicago, Pritzker School of Medicine, neurology residency at UCSF, and a post-doc in the lab at UCSF studying neurotrophic factor signaling.

Ruhi Ahmed, Ph.D., RAC

Vice President of Regulatory and Government Affairs

Ruhi Ahmed joined Inozyme Pharma in April 2017 and serves as Vice President of Regulatory and Government Affairs. She has over 14 years of experience in the pharmaceutical and biotechnology industry in global regulatory drug development and program and portfolio management of assets from the preclinical to the commercial stage. Prior to joining Inozyme Pharma, Dr. Ahmed held positions at Flag Therapeutics Inc., Ultragenyx Pharmaceutical Inc., BioMarin Pharmaceutical Inc., and Actavis Inc. (formerly Watson Pharmaceutical Inc.), where she led the preclinical, clinical and/or manufacturing strategy and submissions for multiple INDs and Marketing Applications for a variety of neuromuscular, respiratory, oncology and metabolic rare diseases. She also led the alliance management and program strategy for several investigational prodrugs, biologics and small molecules. Dr. Ahmed is currently serving as a board member of the Parenteral Drug Association’s (PDA) Regulatory Affairs and Quality Advisory Board and is the U.S. lead of PDA’s Regulatory Affairs Interest Group. She has co-authored the PDA Technical Report on “Quality Risk Management of Biotechnology Manufactured APIs”, as well as other technical reports and book chapters related to risk management and biopharmaceutical manufacturing. Dr. Ahmed earned her B.A. in biology and M.A. in biochemistry from The University of Texas at Austin and her M.Sc. in regulatory sciences and Ph.D. in molecular pharmacology and toxicology from the University of Southern California, Los Angeles.

Stephen Basso

Vice President of Finance

Stephen Basso joined Inozyme Pharma in October 2017 as Vice President of Finance, bringing a track record of more than 25 years of finance experience in both the Financial Services and Life Sciences industries.  Prior to joining Inozyme, Stephen served as Vice President of Corporate Finance at Alexion Pharmaceuticals where he built and lead the corporate finance function and established the organizations global Financial Planning & Analysis team.  During his tenure, the organization commercialized three products (Soliris, Strensig, and Kanuma) across a 50-country commercial platform.  Additionally, Mr. Basso has held multiple leadership roles at Pfizer where he lead the R&D integration of Pharmacia, combining the R&D product portfolios and global development infrastructure.  Mr. Basso earned a B.S. in business from Providence College and an MBA from Boston College.

Lori Ann Correia, MS, CGC

Director, Clinical Operations and Patient Advocacy

Lori Ann Correia joined Inozyme Pharma in October 2017 and serves as Director of Clinical Operations and Patient Advocacy. Ms. Correia brings over 20 years of experience in drug development for rare genetic diseases in the areas of clinical operations, project management, patient advocacy, and physician education to Inozyme Pharma. Ms. Correia has held various roles at biotechnology companies during her career including, uniQure Inc., Edimer Pharmaceuticals, Shire HGT, and Genzyme Corporation. She is also a consultant to the Adult Polygucosan Body Disease Research Foundation, a patient advocacy group. Prior to working in biotechnology, she was a clinical genetic counselor. Ms. Correia earned a BS in biology from Providence College and a MS in human genetics from Sarah Lawrence College. She is a Certified Genetic Counselor via the American Board of Genetic Counselors.

Joseph Schlessinger, Ph.D.

Chairman

Joseph Schlessinger has been the William H. Prusoff Professor and Chairman of the Department of Pharmacology at Yale University School of Medicine since 2001. He was the Director of the Skirball Institute for Biomolecular Medicine at New York University (NYU) Medical Center from 1998-2001 and the Milton and Helen Kimmelman Professor and Chairman of the Department of Pharmacology at NYU Medical School from 1990-2001. He was a faculty member of the Weizmann Institute from 1978-1991 and the Ruth and Leonard Simon Professor of Cancer Research in the Department of Immunology from 1985-1991. Dr. Schlessinger was a Research Director for Rorer Biotechnology from 1985-1990. He founded Sugen, Inc. in 1991, Plexxikon in 2001, and Kolltan in 2008. Dr. Schlessinger holds a B.Sc. in chemistry and physics and an M.Sc. in chemistry from the Hebrew University in Jerusalem. He earned his Ph.D. in biophysics from the Weizmann Institute of Science in 1974. From 1974-1976, Dr. Schlessinger was a postdoctoral fellow in the Departments of Chemistry and Applied Physics at Cornell University, and from 1977-1978, he was a visiting fellow in the immunology branch of the National Cancer Institute of NIH.

Axel Bolte

Director

Axel Bolte co-founded Inozyme Pharma, together with Demetrios Braddock and Yossi Schlessinger. He serves as the President and Chief Executive Officer. Prior to joining Inozyme Pharma, Mr. Bolte had a successful 16-year career in healthcare venture capital and served as an Investment Advisor to HBM Partners AG, based in Zug, Switzerland, and previously New York City. During his time as a venture capitalist, Axel led multiple biopharma investments and has served on many boards of directors of private and public companies. He is currently a Director of Ophthotech (OPHT), Nabriva Therapeutics (NBRV) and Allena Pharmaceuticals (ALNA). He remains a Venture Partner at HBM Partners AG. Mr. Bolte completed studies in biochemistry and organic chemistry at the University of Cambridge and the Swiss Federal Institute of Technology in Zurich, Switzerland. He also earned an MBA from the University of St. Gallen, Switzerland.

Reinaldo M. Diaz

Director

Reinaldo Diaz is a Venture Partner at Longitude Capital. Concurrent with his position with Longitude Capital, Mr. Diaz is also a Managing Director at Auven Therapeutics. Prior to joining Auven Therapeutics, he was a managing member and Co-founder of Diaz & Altschul Capital Management (D&A Capital). Prior to founding D&A Capital, Mr. Diaz was a Managing Director and Head of the Healthcare Group at Schroder Wertheim & Co. Mr. Diaz started his career at PaineWebber, where he was a key member of the PaineWebber Healthcare Investment Banking Group and President of PaineWebber Development Corporation. Mr. Diaz holds an MBA from Harvard Business School and a B.A. from Harvard University.

Ed Mathers

Director

Ed Mathers joined New Enterprise Associates (NEA) as a partner in August 2008 where he focuses on biotechnology and specialty pharmaceuticals investments. Prior to joining NEA, Mr. Mathers most recently served as Executive Vice President, Corporate Development and Venture, at MedImmune Inc. In this role, he was a member of the leadership team that executed the sale of the company to AstraZeneca for $15.6 billion in 2007. While at MedImmune, Mr. Mathers was responsible for the company’s corporate and business development activities and led the company’s venture capital subsidiary, MedImmune Ventures, Inc. Before joining MedImmune in 2002, he was Vice President, Marketing, Corporate Licensing and Acquisitions at Inhale Therapeutic Systems. Mr. Mathers spent 15 years at Glaxo Wellcome, Inc. (GlaxoSmithKline), where he held positions of increasing responsibility. Mr. Mathers is a director of Liquidia Technologies, Ra Pharmaceuticals NASDAQ:RARX – Chairman), Rhythm Pharmaceuticals, Envisia Therapeutics, Synlogic, Mirna Therapeutics (NASDAQ:MIRN), Lumos Pharma, Amplyx Pharmaceuticals, Senti Biosciences, and ObsEva (NASDAQ:OBSV). He earned his bachelor's degree in chemistry from North Carolina State University.

Martin Edwards, Ph.D.

Director

Martin Edwards is a Senior Partner at Novo Ventures, the venture capital arm of Novo A/S. Previously, Dr. Edwards was Chief Executive Officer of ReNeuron Ltd., from 1998 to 2003, taking the company public in 2001. He was Global Head of Drug Development for Novo Nordisk from 1994 to 1998, Senior Vice President at Novo Nordisk (USA) from 1992 to 1994, and Chief Medical Officer/Vice President at Zymogenetics from 1989 to 1992. Dr. Edwards trained in physiology and medicine in Manchester, UK and in business at Warwick University. In 2009, Dr. Edwards was made Adjunct Professor at CBS SIMI in Copenhagen.

Ruchita Sinha

Board Observer

Ruchita Sinha serves as the Senior Director of Investments for Sanofi Ventures, where she invests in biotherapeutic and digital health investments. Prior to Sanofi, Ruchita was at GE Ventures, where she invested in and built partnerships with innovative healthcare startups. She has more than 15 years of healthcare experience in pharma, biotech, medical devices, and healthcare IT. Prior to GE, Ms. Sinha was at Pfizer’s Corporate Strategy & Portfolio Management group, and a management consultant with LEK Consulting. She started her career with Maxygen, an early stage biotech company. Ms. Sinha earned an MBA from the University of Chicago, an M.S. in cellular and molecular biology from the University of Wisconsin-Madison, and a B.S. in biochemistry from Mount Holyoke College.

Demetrios Braddock, M.D., Ph.D.

Board Observer

Demetrios Braddock is an Associate Professor at Yale University, where he practices hematopathology, and leads a laboratory investigating questions at the intersection of disease pathogenesis and biophysical chemistry. Dr. Braddock has made important contributions to the understanding of the histopathology of disorders of aberrant calcification. As the scientific founder of Inozyme and the Chairperson of the Scientific Advisory Board, Dr. Braddock continues to collaborate with the company. Dr. Braddock was educated at the University of Chicago and trained at the National Institutes of Health in Pathology and Chemical Physics.

Demetrios Braddock, M.D., Ph.D.

Scientific Founder and Chairperson

Demetrios Braddock is an Associate Professor at Yale University, where he practices hematopathology, and leads a laboratory investigating questions at the intersection of disease pathogenesis and biophysical chemistry. Dr. Braddock has made important contributions to the understanding of the histopathology of disorders of aberrant calcification. As the scientific founder of Inozyme and the Chairperson of the Scientific Advisory Board, Dr. Braddock continues to collaborate with the company. Dr. Braddock was educated at the University of Chicago and trained at the National Institutes of Health in Pathology and Chemical Physics.

Joseph Schlessinger, Ph.D.

Joseph Schlessinger has been the William H. Prusoff Professor and Chairman of the Department of Pharmacology at Yale University School of Medicine since 2001. He was the Director of the Skirball Institute for Biomolecular Medicine at New York University (NYU) Medical Center from 1998-2001 and the Milton and Helen Kimmelman Professor and Chairman of the Department of Pharmacology at NYU Medical School from 1990-2001. He was a faculty member of the Weizmann Institute from 1978-1991 and the Ruth and Leonard Simon Professor of Cancer Research in the Department of Immunology from 1985-1991. Dr. Schlessinger was a Research Director for Rorer Biotechnology from 1985-1990. He founded Sugen, Inc. in 1991, Plexxikon in 2001, and Kolltan in 2008. Dr. Schlessinger holds a B.Sc. in chemistry and physics and an M.Sc. in chemistry from the Hebrew University in Jerusalem. He earned his Ph.D. in biophysics from the Weizmann Institute of Science in 1974. From 1974-1976, Dr. Schlessinger was a postdoctoral fellow in the Departments of Chemistry and Applied Physics at Cornell University, and from 1977-1978, he was a visiting fellow in the immunology branch of the National Cancer Institute of NIH.

Enrique M. De La Cruz, Ph.D.

Enrique M. De La Cruz is a Professor of Molecular Biophysics and Biochemistry at Yale University. Dr. De La Cruz’s research program focuses in the areas of ATPase and signaling enzyme regulation and adaptation, and biopolymers of the cytoskeleton. Dr. De La Cruz earned his Ph.D. from Johns Hopkins University School of Medicine and conducted research as a Life Sciences Research Foundation postdoctoral fellow at the Perelman School of Medicine at the University of Pennsylvania before moving to Yale in 2001.

Jon S. Morrow, M.D., Ph.D.

Jon Morrow is the Raymond Yesner Professor of Pathology and chair of the Department of Pathology at the Yale School of Medicine as well as the Chief of Pathology at Yale New Haven Hospital. Dr. Morrow’s laboratory studies focus on understanding the structure, function, and pathology of the spectrin-ankyrin-actin cytoskeleton and the mechanisms by which it mediates membrane receptor and adhesion-complex organization; signal transduction; and vesicle trafficking from the ER to the plasma membrane in neurologic, hematologic, and renal disorders.

Mark A. Lemmon, Ph.D.

Mark Lemmon is the David A. Sackler Professor of Pharmacology, and co-director of the Cancer Biology Institute at Yale University. Previously, he was the George W. Raiziss Professor and Chair of Biochemistry and Biophysics at the University of Pennsylvania Perelman School of Medicine, and an investigator in the Abramson Family Cancer Research Institute. Dr. Lemmon earned his B.A. in biochemistry from the University of Oxford (Hertford College), England, and his Ph.D. in molecular biophysics and biochemistry at Yale. Dr. Lemmon’s laboratory focuses on mechanistic, structural, and biochemical aspects of signaling by growth factor receptor tyrosine kinases such as EGF receptor family members, and through phosphoinositides—having defined pleckstrin homology (PH) domain function, for example. He was elected as a Fellow of the Royal Society (FRS) in 2016.

Edward Y. Skolnik, M.D.

Edward Y. Skolnik is the Norman S. Wikler Professor of Medicine and Director of the Division of Nephrology at the New York University Langone Medical Center.  His current research interests are on the regulation and function of the potassium channel KCa3.1 in lymphocyte and mast cell activation, and the role of histidine phosphorylation and dephosphorylation in regulating KCa3.1 and other biological processes.  The ultimate goal of these studies are to identify new targets to inhibit lymphocyte and mast cell activation and thereby treat autoimmune disease and allergy and new targets to promote lymphocyte activation to enhance anti-tumor immunity.  In addition, Dr. Skolnik’s lab studies autosomal dominant polycystic kidney disease which is the most common hereditary cause of renal failure world wide.  Dr. Skolnik has received many awards for his research including election to the American Society of Clinical Investigation, American Association of Physicians, and the Interurban Clinical Club to name a few.

Robert Terkeltaub, M.D.

Robert Terkeltaub is a McGill University medical graduate, and completed Medicine Residency and Rheumatology Fellowship. After Immunopathology postdoctoral research training at Scripps Research Institute, La Jolla, CA, he joined the University of California San Diego faculty in 1985, and serves as Professor of Medicine. Dr. Terkeltaub’s research achievements include works in translational inflammation and skeletal and arterial biology, clinical trials, management guidelines, and outcomes. With lab trainees and mentees, he published pioneering work in innate immunity-modulated and metabolically regulated chondrocyte pro-catabolic and pro-calcifying differentiation therapy targets for diseases of pathologic calcification and tissue degeneration. This includes seminal molecular identification of ENPP1 as the principal chondrocyte PPi-generating ectoenzyme. He identified autosomal recessive ENPP1 deficiency as molecular and genetic etiology of the severe arterial-periarticular calcifying orphan disease General Arterial Calcification of Infancy (GACI). This work led to broader recognition of GACI, genetic screening protocols, and now the development of biologic ENPP1 replacement therapy. He serves on multiple editorial boards and NIH and foundation scientific advisory committees.

Michael Levine, M.D.

Chairperson

Michael A. Levine is chief of the division of endocrinology and diabetes and director of the Center for Bone Health at The Children’s Hospital of Philadelphia. Dr. Levine holds the Lester Baker Endowed Chair in Pediatric Diabetes. His primary clinical interests are endocrine diseases and genetic disorders that affect bone and mineral metabolism. Dr. Levine has an active laboratory research program that complements and extends his clinical and translational studies. He has identified the molecular basis of several inherited disorders of mineral metabolism and his research interests extend to the molecular basis for embryological development of the parathyroid glands and disorders of vitamin D metabolism. Dr. Levine has published nearly 300 manuscripts, chapters and reviews. He is a founding executive editor for the Journal of Clinical and Translational Science and an Associate Editor of the Journal of Clinical Endocrinology and Metabolism. He is also a member of numerous professional societies, including the American Society for Bone and Mineral Research, American Society for Clinical Investigation, Association of American Physicians, and the American Pediatric Society. Dr. Levine is a Fellow of the American College of Physicians and the American Academy of Pediatrics and a Master of the American College of Endocrinology.

Thomas O. Carpenter, M.D.

Thomas Carpenter is professor of pediatrics (endocrinology) and orthopedics and rehabilitation at the Yale School of Medicine. After undergraduate studies at the University of Virginia, Dr. Carpenter earned his medical degree and general pediatrics training at the University of Alabama. His fellowship training in endocrinology at Boston Children’s Hospital began his career-long involvement in clinical research focused on metabolic bone diseases in children. Dr. Carpenter has been at Yale for more than 30 years and is very active in the Yale Bone Program. He serves as director of Yale’s interdisciplinary Pediatric Metabolic Bone Disease clinic, and is director of the Yale Center for X-Linked Hypophosphatemia, which was founded as an  NIH Center of Research Translation in 2006.  The center concentrates on translational science of XLH and related disorders, and serves as a nucleus for the clinical care of families with XLH in the Eastern US. Dr. Carpenter also serves as medical director of the Yale Center for Clinical Investigation’s Hospital Research Unit. Dr. Carpenter has served on various editorial boards of Pediatric, Endocrinology, and Bone journals, and has authored over 150 articles, reviews, and book chapters related to metabolic bone disease in children.

Frank Rutsch, M.D.

Frank Rutsch is an associate professor in pediatrics at Münster University Children’s Hospital, Münster, Germany. Dr. Rutsch graduated from Münster University Medical School in 1992 and took part in the pediatric residency program in Dresden University and Dortmund Municipal Hospital, Germany. After spending a postdoctoral research fellowship at the Department of Rheumatology and Immunology, University of California, San Diego, he became the leader of an independent research group at Münster University Children’s Hospital in 2004. Dr. Rutsch’s main research interests are focused on the discovery of the underlying genetic defects and translational aspects in rare pediatric metabolic and autoimmune disorders. In this respect, with the help of several consortia, his group discovered the genetic cause of generalized arterial calcification of infancy, Crisponi syndrome, certain defects of intracellular cobalamin metabolism, subtypes of Aicardi-Goutières syndrome and Singleton-Merten syndrome. His current projects include experimental studies in animal models of some of these rare disorders.